Aytu BioPharma, Inc. (AYTU)
USD 1.31
(-1.88%)
USD 1.31
(-1.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -1.01 Million USD | 71.2% |
| 2023 | -3.51 Million USD | -118.41% |
| 2022 | -27.95 Million USD | 384.88% |
| 2021 | -29.03 Million USD | 41.12% |
| 2020 | -12.2 Million USD | -463.2% |
| 2019 | -14.11 Million USD | 51.31% |
| 2018 | -15.25 Million USD | 38.08% |
| 2017 | -18.13 Million USD | -8.75% |
| 2016 | -21.81 Million USD | -77.39% |
| 2015 | -7.51 Million USD | -20.24% |
| 2014 | -52.7 Thousand USD | -13064.3% |
| 2013 | -47.47 Thousand USD | 5.45% |
| 2012 | -50.2 Thousand USD | 60.42% |
| 2011 | -126.85 Thousand USD | -165.22% |
| 2010 | -47.28 Thousand USD | -0.61% |
| 2009 | -47.53 Thousand USD | -0.15% |
| 2008 | -47.46 Thousand USD | -17.29% |
| 2007 | -40.47 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -2.46 Million USD | -118.53% |
| 2024 Q1 | -1.5 Million USD | 212.38% |
| 2024 Q4 | -4.72 Million USD | -610.21% |
| 2024 Q2 | 2.36 Million USD | 525.76% |
| 2023 Q4 | 8.01 Million USD | 187.25% |
| 2023 Q3 | -9.19 Million USD | -1022.1% |
| 2023 FY | - USD | -118.41% |
| 2023 Q1 | 803 Thousand USD | -77.44% |
| 2023 Q2 | -819 Thousand USD | -201.99% |
| 2022 Q3 | 36.75 Million USD | 540.63% |
| 2022 Q4 | 3.55 Million USD | -90.32% |
| 2022 FY | - USD | 384.88% |
| 2022 Q2 | -8.34 Million USD | -159.15% |
| 2022 Q1 | 14.1 Million USD | 223.66% |
| 2021 Q1 | -1.46 Million USD | 83.13% |
| 2021 Q4 | -11.4 Million USD | -56.25% |
| 2021 Q2 | -83.61 Thousand USD | 94.3% |
| 2021 Q3 | -7.29 Million USD | -8629.29% |
| 2021 FY | - USD | 41.12% |
| 2020 Q4 | -8.69 Million USD | -174.17% |
| 2020 FY | - USD | -463.2% |
| 2020 Q3 | -3.17 Million USD | 65.59% |
| 2020 Q1 | -3.86 Million USD | -164.6% |
| 2020 Q2 | -9.21 Million USD | -138.2% |
| 2019 Q2 | -4.03 Million USD | -41.14% |
| 2019 Q1 | -2.86 Million USD | -317.61% |
| 2019 Q4 | 5.98 Million USD | 268.52% |
| 2019 FY | - USD | 51.31% |
| 2019 Q3 | -3.55 Million USD | 11.99% |
| 2018 Q1 | -3.7 Million USD | -1456.13% |
| 2018 FY | - USD | 38.08% |
| 2018 Q4 | 1.31 Million USD | 140.39% |
| 2018 Q3 | -3.25 Million USD | 2.33% |
| 2018 Q2 | -3.33 Million USD | 10.01% |
| 2017 Q3 | -4.31 Million USD | -30.96% |
| 2017 Q2 | -3.29 Million USD | 35.89% |
| 2017 Q4 | 273.03 Thousand USD | 106.32% |
| 2017 FY | - USD | -8.75% |
| 2017 Q1 | -5.14 Million USD | 5.08% |
| 2016 Q3 | -3.03 Million USD | -4.68% |
| 2016 Q4 | -5.41 Million USD | -78.5% |
| 2016 Q1 | -2.03 Million USD | 3.45% |
| 2016 Q2 | -2.9 Million USD | -42.59% |
| 2016 FY | - USD | -77.39% |
| 2015 Q1 | -9597.00 USD | 3.41% |
| 2015 Q4 | -2.1 Million USD | -16.65% |
| 2015 Q3 | -1.8 Million USD | -12714.03% |
| 2015 Q2 | -14.09 Thousand USD | -46.87% |
| 2015 FY | - USD | -20.24% |
| 2014 Q1 | -7879.00 USD | 26.67% |
| 2014 Q2 | -13.81 Thousand USD | -75.3% |
| 2014 Q4 | -9936.00 USD | 48.69% |
| 2014 Q3 | -19.36 Thousand USD | -40.2% |
| 2014 FY | - USD | -13064.3% |
| 2013 Q2 | -17.54 Thousand USD | -11.0% |
| 2013 FY | - USD | 5.45% |
| 2013 Q4 | -10.74 Thousand USD | 4.95% |
| 2013 Q3 | -11.3 Thousand USD | 35.58% |
| 2013 Q1 | -15.8 Thousand USD | -64.29% |
| 2012 FY | - USD | 60.42% |
| 2012 Q4 | -9622.00 USD | -27.26% |
| 2012 Q3 | -7561.00 USD | 56.08% |
| 2012 Q2 | -17.21 Thousand USD | 75.08% |
| 2012 Q1 | -69.07 Thousand USD | -277.81% |
| 2011 Q3 | -24.42 Thousand USD | -61.9% |
| 2011 Q2 | -15.08 Thousand USD | -43.18% |
| 2011 Q4 | -18.28 Thousand USD | 25.14% |
| 2011 Q1 | -10.53 Thousand USD | 7.45% |
| 2011 FY | - USD | -165.22% |
| 2010 FY | - USD | -0.61% |
| 2010 Q1 | -8345.00 USD | -24.63% |
| 2010 Q2 | -16.64 Thousand USD | -99.47% |
| 2010 Q3 | -9268.00 USD | 44.32% |
| 2010 Q4 | -11.38 Thousand USD | -22.81% |
| 2009 Q4 | -6696.00 USD | 46.31% |
| 2009 Q3 | -12.47 Thousand USD | 37.72% |
| 2009 Q2 | -20.02 Thousand USD | -105.79% |
| 2009 Q1 | -9731.00 USD | 36.29% |
| 2009 FY | - USD | -0.15% |
| 2008 Q4 | -15.27 Thousand USD | -71.59% |
| 2008 Q3 | -8902.00 USD | 34.36% |
| 2008 Q2 | -13.56 Thousand USD | -21.22% |
| 2008 Q1 | -11.18 Thousand USD | 18.58% |
| 2008 FY | - USD | -17.29% |
| 2007 Q4 | -13.74 Thousand USD | -2.91% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | -13.35 Thousand USD | -147.17% |
| 2007 Q2 | -5402.00 USD | 0.0% |
| 2006 Q4 | -1905.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 99.326% |
| Theratechnologies Inc. | -10.31 Million USD | 90.187% |
| Safety Shot Inc | -12.18 Million USD | 91.695% |
| Cosmos Health Inc. | -17.06 Million USD | 94.069% |
| Cronos Group Inc. | -72.14 Million USD | 98.597% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.891% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 97.195% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 102.809% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 68.523% |
| ProPhase Labs, Inc. | -14.82 Million USD | 93.175% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 77.635% |
| Dynavax Technologies Corporation | 9.66 Million USD | 110.47% |
| Radius Health, Inc. | 38.31 Million USD | 102.642% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 56.955% |
| Alvotech | -484.86 Million USD | 99.791% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 73.538% |
| Alpha Teknova, Inc. | -25.53 Million USD | 96.037% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 99.363% |
| SCYNEXIS, Inc. | 73.47 Million USD | 101.377% |
| Harrow Health, Inc. | 9.72 Million USD | 110.408% |
| Biofrontera Inc. | -18.45 Million USD | 94.516% |
| DURECT Corporation | -24.68 Million USD | 95.9% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 101.03% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 100.926% |
| OptiNose, Inc. | -15.55 Million USD | 93.493% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 103.853% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 185.618% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -42.365% |
| SIGA Technologies, Inc. | 84.15 Million USD | 101.202% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 224.631% |
| Shineco, Inc. | -26.55 Million USD | 96.189% |
| Phibro Animal Health Corporation | 84.6 Million USD | 101.196% |
| Procaps Group S.A. | 104.02 Million USD | 100.973% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 87.954% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 72.026% |
| Viatris Inc. | 3.51 Billion USD | 100.029% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 73.538% |
| Rockwell Medical, Inc. | -4.69 Million USD | 78.441% |
| Incannex Healthcare Limited | -18.5 Million USD | 94.531% |
| Tilray Brands, Inc. | -72.84 Million USD | 98.611% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 100.328% |
| PetIQ, Inc. | 81.48 Million USD | 101.242% |
| Silver Spike Investment Corp. | 7.34 Million USD | 113.787% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 100.243% |
| Journey Medical Corporation | 1.92 Million USD | 152.681% |
| Alimera Sciences, Inc. | 7.27 Million USD | 113.909% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 75.973% |
| Assertio Holdings, Inc. | -222.44 Million USD | 99.545% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 74.641% |
| Embecta Corp. | 245.4 Million USD | 100.412% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 94.948% |
| Procaps Group, S.A. | 104.02 Million USD | 100.973% |
| PainReform Ltd. | -9.56 Million USD | 89.424% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 99.321% |
| Hempacco Co., Inc. | -12.77 Million USD | 92.077% |
| Talphera, Inc. | -9.84 Million USD | 89.718% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 100.621% |
| Alvotech | -484.86 Million USD | 99.791% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.206% |
| Kamada Ltd. | 21.53 Million USD | 104.7% |
| Indivior PLC | 66 Million USD | 101.533% |
| Currenc Group, Inc. | -1.9 Million USD | 46.753% |
| Evoke Pharma, Inc. | -7.29 Million USD | 86.122% |
| Flora Growth Corp. | -45.87 Million USD | 97.794% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 94.948% |
| Evolus, Inc. | -41.81 Million USD | 97.58% |
| HUTCHMED (China) Limited | 25.52 Million USD | 103.964% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 100.419% |
| Akanda Corp. | -27.73 Million USD | 96.351% |